DXCM 53.50 Dexcom Inc $DXCM Hit a 52 week high of 53.50 Closing the day 11/10/14 at 53.50 +2.57 +5.05% With a day low of 50.07 and a total volume of 1,252,198.
DXCM Recent Posts: http://investorshangout.com/DexCom-Inc-DXCM-53952/
DXCM Dexcom Inc Recent Headline News
DexCom G4 Platinum Software Gains FDA Nod, Shares Surge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 1:54PM CST
Following the announcement, shares of DexCom, Inc. (DXCM) shot up nearly 14.12% to close at $50.93 in the last trading session.
ABT: 44.09 (+0.72), JNJ: 108.82 (+0.62), DXCM: 53.50 (+2.57), MDT: 68.71 (+0.61)
DexCom Has Returned 17.2% Since SmarTrend Recommendation (DXCM)
Comtex SmarTrend(R) - Mon Nov 10, 9:32AM CST
SmarTrend identified an Uptrend for DexCom (NASDAQ
XCM) on October 21st, 2014 at $43.32. In approximately 3 weeks, DexCom has returned 17.21% as of today's recent price of $50.77.
DXCM: 53.50 (+2.57)
Strength Seen in DexCom (DXCM): Stocks Gains 14.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:46AM CST
DexCom (DXCM) was a big mover last session, with shares rising over 14% on the day.
ABMD: 32.99 (+0.86), DXCM: 53.50 (+2.57), EW: 124.60 (+1.84), ANGO: 16.96 (+0.01)
Hologic Beats Q4 Earnings, Sales as All Segments Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 1:50PM CST
Hologic (HOLX) entered into an amended license agreement with Roka Bioscience, which earned a one-time revenue benefit of $20.1 million for Hologic
ABMD: 32.99 (+0.86), DXCM: 53.50 (+2.57), ANGO: 16.96 (+0.01), HOLX: 26.55 (+0.34)
Watch Out: Barbarians At The Gate For DexCom (DXCM)
at The Street - Fri Nov 07, 8:55AM CST
Trade-Ideas LLC identified DexCom (DXCM) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
DXCM: 53.50 (+2.57)
Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:59AM CST
Foundation Medicine has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ABMD: 32.99 (+0.86), DXCM: 53.50 (+2.57), FMI: 24.71 (-0.04), ANGO: 16.96 (+0.01)
DexCom's (DXCM) CEO Terry Gregg on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 9:13PM CST
DXCM: 53.50 (+2.57)
DexCom misses by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:09PM CST
DXCM: 53.50 (+2.57)
DexCom (DXCM) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 3:25PM CST
DXCM: 53.50 (+2.57)
DexCom, Inc. Reports Third Quarter 2014 Financial Results
Business Wire - Thu Nov 06, 3:02PM CST
DexCom, Inc. (Nasdaq: DXCM) today reported its unaudited financial results as of and for the quarter ended September 30, 2014.
DXCM: 53.50 (+2.57)
FDA Approves Dexcom Software with Artificial Pancreas Algorithm
Business Wire - Thu Nov 06, 7:30AM CST
Dexcom, Inc., (NASDAQ XCM), a leader in continuous glucose monitoring (CGM), announced today that the U.S. Food and Drug Administration (FDA) has approved new software for the Dexcom G4(R) PLATINUM CGM. The new Software 505 features the same advanced algorithm as used in artificial pancreas research around the world. The software will impact the performance of the Dexcom G4 PLATINUM, already considered the most accurate CGM system on the market today. The software will be made available free of charge to adult patients using the Dexcom G4 PLATINUM.
DXCM: 53.50 (+2.57)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:35PM CST
BEBE: 2.38 (-0.02), ACET: 21.41 (+0.38), ANET: 76.79 (-1.04), FNGN: 31.35 (-0.04), CPST: 0.95 (+0.05), AUQ: 3.21 (-0.09), AMRN: 0.83 (-0.07), ED: 63.47 (-0.10), ENV: 52.12 (-0.04), FXCM: 16.58 (+0.77), BCEI: 40.19 (-3.18), GXP: 27.15 (+0.15), EAC: 12.95 (-0.17), DXCM: 53.50 (+2.57), CSC: 59.31 (-0.36), AEL: 27.84 (+0.64), HNSN: 0.75 (-0.08), CFN: 57.52 (+0.24), ANAC: 30.54 (+1.94), DAR: 18.77 (-0.03), GST: 4.02 (-0.08), ARC: 10.17 (+0.10), FIVN: 4.83 (-0.25), ELON: 2.03 (+0.03), FSLR: 51.96 (+1.67), EZPW: 10.99 (+0.11), ALIM: 5.14 (+0.08), FWM: 2.43 (-0.03), BRS: 71.07 (-2.56), ECOM: 18.34 (+0.49), FTEK: 4.05 (-0.13), CVT: 28.51 (+1.26), AL: 37.74 (+0.14), BBRG: 12.62 (-0.03), BPZ: 0.96 (unch), ECPG: 45.23 (-0.18), HTGC: 16.10 (-0.03), AIRM: 43.48 (+0.53), BNFT: 25.50 (+0.80), ENOC: 15.05 (+0.05), HPTX: 21.58 (-0.24), AGO: 24.58 (+0.05), FICO: 70.73 (+0.39), FF: 13.05 (-0.47), FI: 19.08 (-0.24), EVC: 5.14 (-0.05), EBS: 23.95 (unch), ABCO: 47.46 (-1.01), DIOD: 26.04 (+0.16), DIS: 89.78 (-0.22), EGOV: 17.01 (+0.21), APEI: 36.05 (+0.81), DVA: 74.72 (+0.23), CLVS: 60.14 (+1.83), HCI: 43.91 (+0.80), BRKR: 17.94 (+0.03), HGR: 20.59 (+0.71)
DexCom Announces Upcoming Conference Presentations
Business Wire - Thu Oct 30, 7:30AM CDT
DexCom, Inc. (NASDAQ XCM) today announced that management will present an update on DexCom at the following upcoming investor conferences:
DXCM: 53.50 (+2.57)
Forget MannKind Corporation: 3 Better Stocks
Motley Fool Staff - Motley Fool - Mon Oct 27, 8:13AM CDT
Source: MannKind. A doubling of Americans diagnosed with diabetes over the coming decade may support demand for MannKind 's inhalable insulin Afrezza, but that doesn't necessarily mean that MannKind is biotech's best idea. We asked three of...
DXCM: 53.50 (+2.57), NVAX: 5.21 (+0.26), AGIO: 81.78 (+9.72), SNY: 46.19 (+0.50), MNKD: 5.88 (+0.10), CELG: 108.01 (+1.56)
DexCom reports November 6
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 9:43AM CDT
DXCM: 53.50 (+2.57)
DexCom Schedules Third Quarter 2014 Earnings Release and Conference Call for November 6, 2014 at 4:30 p.m. Eastern Time
Business Wire - Thu Oct 23, 7:31AM CDT
DexCom, Inc. (NASDAQ XCM) today announced that it plans to release its third quarter 2014 financial results after market close on Thursday, November 6, 2014. Management will hold a conference call to review the company's third quarter 2014 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com by navigating to "Our Company," then "Investor Relations," and then "Events and Webcasts," and will be archived there for future reference.
DXCM: 53.50 (+2.57)
FDA Approves Dexcom SHARE(TM), the First Remote Mobile Communications Device Used for Continuous Glucose Monitoring (CGM)
Business Wire - Mon Oct 20, 8:24AM CDT
Dexcom, Inc. (NASDAQ XCM), a leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its CGM remote mobile communications device: Dexcom SHARE. Dexcom SHARE, an accessory to the Dexcom G4(R) PLATINUM Continuous Glucose Monitoring System, uses a secure wireless connection to transmit the glucose levels of a person with diabetes to the smartphones of up to five designated recipients, or "followers." These followers can remotely monitor a patient's glucose information and receive alert notifications from almost anywhere via their Apple(R) iPhone(R) or iPod(R) touch. With Dexcom SHARE, parents and personal caregivers can monitor a child's or loved one's glucose data from a remote location, giving them peace of mind and reassurance when they are apart.
DXCM: 53.50 (+2.57)
MFG, PGTI, MWIV, BKD, AREX, DXCM Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Oct 06, 6:29AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Mizuho Financial Group Inc (NYSE:MFG), PGT Inc (NASDAQ
GTI), MWI Veterinary Supply Inc (NASDAQ:MWIV), BROOKDALE SENIOR LIVING INC. (NYSE:BKD), Approach Resources Inc (NASDAQ:AREX), DexCom Inc (NASDAQ XCM) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
MFG: 3.61 (+0.05), DXCM: 53.50 (+2.57), MWIV: 154.83 (+0.59), PGTI: 9.71 (+0.09), BKD: 33.08 (+0.62), AREX: 10.61 (-0.12)
The Stunning Mobile Game Changer for Diabetics That Investors Can't Ignore
Leo Sun, The Motley Fool - Motley Fool - Sun Oct 05, 8:31AM CDT
Ever since Apple launched the first iPhone nearly seven years ago, developers have released mobile apps and connected devices to improve the lives of diabetes patients. These products helped diabetics track meals, insulin dosages, glucose...
JNJ: 108.82 (+0.62), DXCM: 53.50 (+2.57), MDT: 68.71 (+0.61), SNY: 46.19 (+0.50), AAPL: 108.83 (-0.18)
Technical Report on Health Care Equipment Stocks - Baxter Intl., Covidien, Becton Dickinson, Thoratec, and DexCom
PR Newswire - Wed Sep 17, 8:05AM CDT
On Tuesday, September 16, 2014, the NASDAQ Composite ended at 4,552.76, up 0.75%, the Dow Jones Industrial Average advanced 0.59%, to finish the day at 17,131.97, and the S&P 500 closed at 1,998.98, up 0.75%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.20, up 1.34%, with the index also advancing 7.96% in the previous three months. Investor-Edge has initiated coverage on the following equities: Baxter International Inc. (NYSE: BAX), Covidien PLC (NYSE: COV), Becton Dickinson and Company (NYSE: BDX), Thoratec Corporation (NASDAQ: THOR), and DexCom Inc. (NASDAQ: DXCM). Free research on these five companies can be accessed at:
BDX: 128.30 (+2.76), DXCM: 53.50 (+2.57), BAX: 70.63 (+0.02), COV: 93.64 (+1.56), THOR: 27.30 (+0.37)
DXCM Recent Posts: http://investorshangout.com/DexCom-Inc-DXCM-53952/
DXCM Dexcom Inc Recent Headline News
DexCom G4 Platinum Software Gains FDA Nod, Shares Surge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 1:54PM CST
Following the announcement, shares of DexCom, Inc. (DXCM) shot up nearly 14.12% to close at $50.93 in the last trading session.
ABT: 44.09 (+0.72), JNJ: 108.82 (+0.62), DXCM: 53.50 (+2.57), MDT: 68.71 (+0.61)
DexCom Has Returned 17.2% Since SmarTrend Recommendation (DXCM)
Comtex SmarTrend(R) - Mon Nov 10, 9:32AM CST
SmarTrend identified an Uptrend for DexCom (NASDAQ
XCM) on October 21st, 2014 at $43.32. In approximately 3 weeks, DexCom has returned 17.21% as of today's recent price of $50.77. DXCM: 53.50 (+2.57)
Strength Seen in DexCom (DXCM): Stocks Gains 14.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:46AM CST
DexCom (DXCM) was a big mover last session, with shares rising over 14% on the day.
ABMD: 32.99 (+0.86), DXCM: 53.50 (+2.57), EW: 124.60 (+1.84), ANGO: 16.96 (+0.01)
Hologic Beats Q4 Earnings, Sales as All Segments Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 1:50PM CST
Hologic (HOLX) entered into an amended license agreement with Roka Bioscience, which earned a one-time revenue benefit of $20.1 million for Hologic
ABMD: 32.99 (+0.86), DXCM: 53.50 (+2.57), ANGO: 16.96 (+0.01), HOLX: 26.55 (+0.34)
Watch Out: Barbarians At The Gate For DexCom (DXCM)
at The Street - Fri Nov 07, 8:55AM CST
Trade-Ideas LLC identified DexCom (DXCM) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
DXCM: 53.50 (+2.57)
Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:59AM CST
Foundation Medicine has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ABMD: 32.99 (+0.86), DXCM: 53.50 (+2.57), FMI: 24.71 (-0.04), ANGO: 16.96 (+0.01)
DexCom's (DXCM) CEO Terry Gregg on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 9:13PM CST
DXCM: 53.50 (+2.57)
DexCom misses by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:09PM CST
DXCM: 53.50 (+2.57)
DexCom (DXCM) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 3:25PM CST
DXCM: 53.50 (+2.57)
DexCom, Inc. Reports Third Quarter 2014 Financial Results
Business Wire - Thu Nov 06, 3:02PM CST
DexCom, Inc. (Nasdaq: DXCM) today reported its unaudited financial results as of and for the quarter ended September 30, 2014.
DXCM: 53.50 (+2.57)
FDA Approves Dexcom Software with Artificial Pancreas Algorithm
Business Wire - Thu Nov 06, 7:30AM CST
Dexcom, Inc., (NASDAQ
XCM), a leader in continuous glucose monitoring (CGM), announced today that the U.S. Food and Drug Administration (FDA) has approved new software for the Dexcom G4(R) PLATINUM CGM. The new Software 505 features the same advanced algorithm as used in artificial pancreas research around the world. The software will impact the performance of the Dexcom G4 PLATINUM, already considered the most accurate CGM system on the market today. The software will be made available free of charge to adult patients using the Dexcom G4 PLATINUM. DXCM: 53.50 (+2.57)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:35PM CST
BEBE: 2.38 (-0.02), ACET: 21.41 (+0.38), ANET: 76.79 (-1.04), FNGN: 31.35 (-0.04), CPST: 0.95 (+0.05), AUQ: 3.21 (-0.09), AMRN: 0.83 (-0.07), ED: 63.47 (-0.10), ENV: 52.12 (-0.04), FXCM: 16.58 (+0.77), BCEI: 40.19 (-3.18), GXP: 27.15 (+0.15), EAC: 12.95 (-0.17), DXCM: 53.50 (+2.57), CSC: 59.31 (-0.36), AEL: 27.84 (+0.64), HNSN: 0.75 (-0.08), CFN: 57.52 (+0.24), ANAC: 30.54 (+1.94), DAR: 18.77 (-0.03), GST: 4.02 (-0.08), ARC: 10.17 (+0.10), FIVN: 4.83 (-0.25), ELON: 2.03 (+0.03), FSLR: 51.96 (+1.67), EZPW: 10.99 (+0.11), ALIM: 5.14 (+0.08), FWM: 2.43 (-0.03), BRS: 71.07 (-2.56), ECOM: 18.34 (+0.49), FTEK: 4.05 (-0.13), CVT: 28.51 (+1.26), AL: 37.74 (+0.14), BBRG: 12.62 (-0.03), BPZ: 0.96 (unch), ECPG: 45.23 (-0.18), HTGC: 16.10 (-0.03), AIRM: 43.48 (+0.53), BNFT: 25.50 (+0.80), ENOC: 15.05 (+0.05), HPTX: 21.58 (-0.24), AGO: 24.58 (+0.05), FICO: 70.73 (+0.39), FF: 13.05 (-0.47), FI: 19.08 (-0.24), EVC: 5.14 (-0.05), EBS: 23.95 (unch), ABCO: 47.46 (-1.01), DIOD: 26.04 (+0.16), DIS: 89.78 (-0.22), EGOV: 17.01 (+0.21), APEI: 36.05 (+0.81), DVA: 74.72 (+0.23), CLVS: 60.14 (+1.83), HCI: 43.91 (+0.80), BRKR: 17.94 (+0.03), HGR: 20.59 (+0.71)
DexCom Announces Upcoming Conference Presentations
Business Wire - Thu Oct 30, 7:30AM CDT
DexCom, Inc. (NASDAQ
XCM) today announced that management will present an update on DexCom at the following upcoming investor conferences: DXCM: 53.50 (+2.57)
Forget MannKind Corporation: 3 Better Stocks
Motley Fool Staff - Motley Fool - Mon Oct 27, 8:13AM CDT
Source: MannKind. A doubling of Americans diagnosed with diabetes over the coming decade may support demand for MannKind 's inhalable insulin Afrezza, but that doesn't necessarily mean that MannKind is biotech's best idea. We asked three of...
DXCM: 53.50 (+2.57), NVAX: 5.21 (+0.26), AGIO: 81.78 (+9.72), SNY: 46.19 (+0.50), MNKD: 5.88 (+0.10), CELG: 108.01 (+1.56)
DexCom reports November 6
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 9:43AM CDT
DXCM: 53.50 (+2.57)
DexCom Schedules Third Quarter 2014 Earnings Release and Conference Call for November 6, 2014 at 4:30 p.m. Eastern Time
Business Wire - Thu Oct 23, 7:31AM CDT
DexCom, Inc. (NASDAQ
XCM) today announced that it plans to release its third quarter 2014 financial results after market close on Thursday, November 6, 2014. Management will hold a conference call to review the company's third quarter 2014 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com by navigating to "Our Company," then "Investor Relations," and then "Events and Webcasts," and will be archived there for future reference. DXCM: 53.50 (+2.57)
FDA Approves Dexcom SHARE(TM), the First Remote Mobile Communications Device Used for Continuous Glucose Monitoring (CGM)
Business Wire - Mon Oct 20, 8:24AM CDT
Dexcom, Inc. (NASDAQ
XCM), a leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its CGM remote mobile communications device: Dexcom SHARE. Dexcom SHARE, an accessory to the Dexcom G4(R) PLATINUM Continuous Glucose Monitoring System, uses a secure wireless connection to transmit the glucose levels of a person with diabetes to the smartphones of up to five designated recipients, or "followers." These followers can remotely monitor a patient's glucose information and receive alert notifications from almost anywhere via their Apple(R) iPhone(R) or iPod(R) touch. With Dexcom SHARE, parents and personal caregivers can monitor a child's or loved one's glucose data from a remote location, giving them peace of mind and reassurance when they are apart. DXCM: 53.50 (+2.57)
MFG, PGTI, MWIV, BKD, AREX, DXCM Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Oct 06, 6:29AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Mizuho Financial Group Inc (NYSE:MFG), PGT Inc (NASDAQ
GTI), MWI Veterinary Supply Inc (NASDAQ:MWIV), BROOKDALE SENIOR LIVING INC. (NYSE:BKD), Approach Resources Inc (NASDAQ:AREX), DexCom Inc (NASDAQ XCM) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: MFG: 3.61 (+0.05), DXCM: 53.50 (+2.57), MWIV: 154.83 (+0.59), PGTI: 9.71 (+0.09), BKD: 33.08 (+0.62), AREX: 10.61 (-0.12)
The Stunning Mobile Game Changer for Diabetics That Investors Can't Ignore
Leo Sun, The Motley Fool - Motley Fool - Sun Oct 05, 8:31AM CDT
Ever since Apple launched the first iPhone nearly seven years ago, developers have released mobile apps and connected devices to improve the lives of diabetes patients. These products helped diabetics track meals, insulin dosages, glucose...
JNJ: 108.82 (+0.62), DXCM: 53.50 (+2.57), MDT: 68.71 (+0.61), SNY: 46.19 (+0.50), AAPL: 108.83 (-0.18)
Technical Report on Health Care Equipment Stocks - Baxter Intl., Covidien, Becton Dickinson, Thoratec, and DexCom
PR Newswire - Wed Sep 17, 8:05AM CDT
On Tuesday, September 16, 2014, the NASDAQ Composite ended at 4,552.76, up 0.75%, the Dow Jones Industrial Average advanced 0.59%, to finish the day at 17,131.97, and the S&P 500 closed at 1,998.98, up 0.75%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.20, up 1.34%, with the index also advancing 7.96% in the previous three months. Investor-Edge has initiated coverage on the following equities: Baxter International Inc. (NYSE: BAX), Covidien PLC (NYSE: COV), Becton Dickinson and Company (NYSE: BDX), Thoratec Corporation (NASDAQ: THOR), and DexCom Inc. (NASDAQ: DXCM). Free research on these five companies can be accessed at:
BDX: 128.30 (+2.76), DXCM: 53.50 (+2.57), BAX: 70.63 (+0.02), COV: 93.64 (+1.56), THOR: 27.30 (+0.37)
